Reconceptualizing Risk-Benefit Assessment of Novel Cancer Therapies to Expand Global Access and Reduce Worldwide Mortality
JAMA Oncol
.
2022 Feb 1;8(2):203-204.
doi: 10.1001/jamaoncol.2021.5945.
Authors
Rebecca J DeBoer
1
,
Hope S Rugo
1
,
Lawrence N Shulman
2
Affiliations
1
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco.
2
Abramson Cancer Center, University of Pennsylvania, Philadelphia.
PMID:
34882172
DOI:
10.1001/jamaoncol.2021.5945
No abstract available
MeSH terms
Global Health
Humans
Neoplasms* / drug therapy
Risk Assessment